Increased Soluble PD-1 Predicts Response to Nivolumab plus Ipilimumab in Melanoma

SIMPLE SUMMARY: Checkpoint inhibitors have emerged as an effective therapy for patients with metastatic melanoma significantly improving survival for these patients. Despite this, many patients do not respond to the therapy and no current biomarkers can identify responders from non-responders. Using...

Descripción completa

Detalles Bibliográficos
Autores principales: Pedersen, Jesper Geert, Sokac, Mateo, Sørensen, Boe Sandahl, Luczak, Adam Andrzej, Aggerholm-Pedersen, Ninna, Birkbak, Nicolai Juul, Øllegaard, Trine Heide, Jakobsen, Martin Roelsgaard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9322974/
https://www.ncbi.nlm.nih.gov/pubmed/35884403
http://dx.doi.org/10.3390/cancers14143342

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9322974/
https://www.ncbi.nlm.nih.gov/pubmed/35884403
http://dx.doi.org/10.3390/cancers14143342

Ejemplares similares